Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q3 FY23 results · Oct–Dec 2022
Gufic Biosciences reported revenue from operations of ₹177.47 crore (up 3.1% from Q3 FY22) and net profit of ₹20.34 crore (down 3.3% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a standalone basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 177.47 | 172.07 | +3.1% | 174.84 | +1.5% |
| Other income | 0.76 | 1.53 | −50.5% | 0.82 | −7.5% |
| Total income | 178.23 | 173.60 | +2.7% | 175.65 | +1.5% |
| Profit before tax | 27.25 | 28.73 | −5.2% | 27.26 | −0.0% |
| Net profit for the period | 20.34 | 21.03 | −3.3% | 20.21 | +0.6% |
| EPS, basic (₹) | 2.10 | 2.17 | −3.2% | 2.09 | +0.5% |
| Net margin (%) | 11.5 | 12.2 | 11.6 |
Standalone
- Filed with BSE
- 16 Feb 2023, 12:04 IST
- Board meeting
- 10 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE